Sorted By Test Name - Mayo Medical Laboratories

FABP
91408
82091
hours of onset; levels return to normal by the third or fourth day. A 4-6 fold elevation of amylase activity
above the reference limit is usual with the maximal levels obtained in 12-72 hours. However, a significant
number of subjects show lesser elevations and sometimes none. The magnitude of the elevation of serum
enzyme activity is not related to the severity of pancreatic involvement. Normalization is not necessarily a
sign of resolution. In acute pancreatitis associated with hyperlipidemia, serum amylase activity may be
spuriously normal; the amylasemia may be unmasked either by serial dilution of the serum or
ultracentrifugation. A significant amount of serum amylase is excreted in the urine, and therefore,
elevation of serum activity is reflected in the rise of urinary amylase activity. Urine amylase, as compared
to serum amylase, appears to be more frequently elevated, reaches higher levels and persists for longer
periods. However, the receiver operator curves (ROC) of various serum and urine amylase assays
demonstrated that all urine assays had poorer diagnostic utility than all serum assays. In quiescent chronic
pancreatitis, both serum and urine activities are usually subnormal. Because it is produced by several
organs, amylase is not a specific indicator of pancreatic function. Elevated levels also may be seen in a
number of non-pancreatic disease processes including mumps, salivary duct obstruction, ectopic
pregnancy, and intestinal obstruction/ infarction.
Reference Values:
0-30 days: 0-6 U/L
31-182 days: 1-17 U/L
183-365 days: 6-44 U/L
1-3 years: 8-79 U/L
4-17 years: 21-110 U/L
> or =18 years: 26-102 U/L
Clinical References: 1. Soldin SJ, et al: Pediatric Reference Ranges, AACC Press, Washington DC
1997 2. Tietz Textbook of Clinical Chemistry. Editors Burtis and Ashwood. WB Saunders Company,
Philadelphia, 1999 3. Swaroop VS, Chari ST, Clain JE: Acute pancreatitis, JAMA 2004; 291:2865-2868
Amyloid Beta-Protein
Reference Values:
Adult Reference Range(s):
20-80 pg/ml
This test was developed and its performance characteristics determined by Inter Science Institute. It has
not been cleared or approved by the US Food and Drug Administration. The FDA has determined that
such clearance or approval is not necessary.
Test Performed by: Inter Science Inst
944 West Hyde Park
Inglewood, CA 90302
Amyloid Protein Identification, Paraffin, LC MS/MS
Clinical Information: Certain diseases are caused by abnormal deposition of proteins in extracellular
sites. An example is amyloid which consists of several subtypes--systemic, familial, localized, and
secondary. Each subtype is caused by a different protein. Because the management of amyloidosis relies
on the treatment of the underlying etiology and differs radically for different amyloid subtypes, accurate
characterization of the amyloid fibrils is important. This assay identifies the proteins associated with
extracellular deposits including the proteins important in typing amyloidosis: for instance, ATTR
(transthyretin/prealbumin; familial amyloidosis), AA (serum amyloid A), SAA (secondary amyloidosis),
and AL (immunoglobulin light chain, lambda or kappa; primary amyloidosis).
Useful For: Identification of proteins associated with extracellular deposits, including amyloidosis This
test is appropriate for all tissue types in routinely processed paraffin- embedded biopsy specimens
Interpretation: This test will be processed as a pathology consultation. An interpretation will be
Current as of January 4, 2013 7:15 pm CST 800-533-1710 or 507-266-5700 or MayoMedicalLaboratories.com Page 133